Top Medical News
an hour ago
In patients with localized prostate cancer undergoing external beam radiotherapy, use of the orally administered androgen deprivation therapy relugolix results in rapid and sustained suppression of testosterone to castrate levels, with a tolerable safety profile, according to the results of a phase II trial.
12 hours ago
Obesity appears to be a strong risk factor for liver-related mortality, while exercise exerts a protective effect, a recent study has found.
Pearl Toh, 15 hours ago
Adults do not need booster shots for tetanus or diphtheria if they have already completed their vaccination course against these diseases during childhood, a study suggests.
16 hours ago
Excessive levels of uric acid in the blood are a risk factor for hypertension, independent of alcohol consumption, a study has found.
18 hours ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
19 hours ago
Mirabegron add-on therapy is both safe and effective in the treatment of men with overactive bladder symptoms receiving tamsulosin for benign prostatic hyperplasia, according to the results of a randomized, phase IV study.
21 hours ago
Amid the coronavirus disease 2019 (COVID-19) pandemic, elderly participants of clinical research studies believe that medical centres can ensure safety, a recent study has found.
Special Reports
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).
11 May 2020
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.
05 May 2020
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.
Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Audrey Abella, 23 Apr 2020
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Pearl Toh, 23 Apr 2020
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
08 Apr 2020
This is the first issue in a series of five articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data release. This issue brings insight to the trial’s background, study design and key results.
Conference Reports
Pearl Toh, 21 May 2020
A levonorgestrel (LNG)-releasing intrauterine device (IUD) maintains high contraceptive efficacy up to 6 years, which is beyond the 5-year period it is currently approved for, according to data from the Mirena Extension Trial (MET) released during the ACOG 2020 Meeting.
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Roshini Claire Anthony, 18 May 2020

Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

Pearl Toh, 14 May 2020
Children with high serum insulin levels and whose parents are under stress are more likely to have asthma symptoms, suggest two studies presented at the AAAAI 2020 Meeting.
Roshini Claire Anthony, 14 May 2020

The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.

Audrey Abella, 14 May 2020
The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.
Pearl Toh, 13 May 2020
The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download